<span style=textdecoration: underline;>Ro</span>botic vs <span style=textdecoration: underline;>Ta</span>TME Rectal Surgery ROTA STUDY Matched Cohort Trial for Mid to Low Rectal Cancer Surgery Evaluation Trial in the Hands of an Experienced Surgeon

Authors: {'first_name': 'Ravish', 'last_name': 'Jootun'},{'first_name': 'Pedja', 'last_name': 'Cuk'},{'first_name': 'Mark', 'last_name': 'Elleb\xc3\xa6k'},{'first_name': 'Per Vadgaard', 'last_name': 'Andersen'},{'first_name': 'S\xc3\xb8ren', 'last_name': 'Salomon'},{'first_name': 'Gunnar', 'last_name': 'Baatrup'},{'first_name': 'Issam', 'last_name': 'Al-Najami'},{'first_name': 'Jim', 'last_name': 'Khan'}


Background: Recent novel surgical techniques for resection of low rectal cancer have been introduced and these approaches have the potential to overcome anatomical limitations like obesity, narrow male pelvis and bulky and low tumours. Two of these procedures are robotic low anterior resection (RLAR) and transanal total mesorectal excision (TaTME).

Both approaches have distinct advantages and limitations. There has been no head to head trial comparing RLAR and TaTME for patients with mid to low rectal cancer undergoing surgery by experienced surgeons. Previous studies looking at the oncological outcomes of either TaTME or robotic TME included many centres where the surgeons were on a learning curve and hence the true oncological outcomes and clinical benefits can not be measured accurately.

Method: The inclusion criteria include experienced surgeons defined as minimum of 60 prior procedures with RLAR or TaTME. Successful oncological and clinical outcomes are defined as circumferential resection margin (CRM) ≥1 mm with limited postoperative morbidity (absence of Clavien-Dindo grade III–IV complications within 30 days after surgery). Local and distal recurrence rates with DFS over 3 years will be measured as primary outcome.

Data will be collected prospectively and entered in a dedicated database.

Discussion:The primary objective of this study is to conduct a multicentre prospective trial to investigate clinical outcomes, in particular disease free survival (DFS) in patients undergoing RLAR and TaTME. The additional goal is to investigate other efficacy measures, complications rates, health economic aspects and patient reported health related quality of life.

This paper describes an important trial conducted in expert centres to establish the needed knowledge for a detailed comparison of outcomes for TaTME versus RLAR.

This trial is the first comparative study, comparing TaTME and RLAR, seeking to establish foothold for tailor-made surgical treatment of low rectal cancer patients.

Trial registration: The trial is registered in September 2019. id: NCT04200027.

Keywords: Rectal cancerTotal mesorectal excisionRobotic surgerytrans-anal surgery 
 Accepted on 02 Sep 2021            Submitted on 08 Aug 2021


The outcome of surgery for rectal cancer has improved substantially during the past two decades due to the introduction of the TME technique, which involves complete removal of the mesorectum with preservation of the pelvic autonomic nerves. Local recurrence rate of rectal cancer has been reduced [1] because discontinuous cancer cells in the mesorectum are removed by complete resection of this tissue [1, 2, 3].

Minimally invasive surgery is taking over as the preferred approach for colorectal diseases. Recently published randomized clinical trials (RCTs), such as COLOR II, COREAN and CLASICC, have shown better results for laparoscopic total mesorectal excision in terms of short-term and long-term outcomes, when compared with open TME [4, 5, 6].

Sphincter saving TME surgery of ultra low rectal cancer is technically demanding and hold a higher risk of incomplete resection. It is offered to a small fraction of patients in few dedicated centres. TME is limited in patients with low rectal cancer, who require surgeons with experience in ultra-low sphincter-saving laparoscopic surgery, which has a high risk of leaving a positive circumferential resection margin (CRM). In addition, narrow pelvic anatomy; male sex and high body mass index (BMI) are also unfavourable patient characteristics for a laparoscopic approach.

The wish to overcome these challenges has motivated surgeons to explore alternative techniques. The two more recent procedures that have been introduced are robotic low anterior resection (RLAR) and Transanal Total Mesorectal Excision (TaTME). These two new procedures have the potential to overcome anatomical limitations like obesity, narrow male pelvis and bulky and low tumours.

Transanal assissted TME (TaTME) combines the TAMIS (transanal minimally invasive surgery) and trans-abdominal approaches to successfully perform the TME. TaTME typically starts low in the pelvis and progresses to the mobilization of the splenic flexure/sigmoid colon in a “bottom-up” manner [7]. A single-incision laparoscopic surgery port is introduced into the anal canal to gain endoscopic access to the rectum, pneumorectum is established, A purse-string suture is applied below the tumor to ensure an adequate distal margin [8]. Transanal excision is subsequently performed with laparoscopic instruments.

Rectal distension with CO2 combined with magnifying optics permits excellent visualization of tissue planes. Easier access to the low rectum and precise selection of the distal resection margin under direct visualization helps ensure an adequate margin. It has been argued that TaTME may lead to a safer anastomosis by avoiding the multiple stapler firings often required in the laparoscopic approach and may result in higher rates of sphincter preserving surgery.

The robotic approach has been subject to much interest in recent years because of its potential learning benefits and clinical benefits to the patients. Some of the clinical benefits include shorter hospital stay and improved functional outcomes compared to laparoscopic surgery [9].

These advantages provided by the robotic platform hold the potential to provide improved clinical outcomes [10, 11, 12].

Both of the mentioned procedures have been compared retrospectively to open and conventional laparoscopic surgery in more trials showing that these methods are safe and feasible [8, 13]. However direct comparison of these two techniques are still lacking.

Potential benefits of robotic rectal resections

Technical Benefits

The potential benefits of robotic systems over laparoscopic TME include superior three-dimensional vision, seven degrees of freedom of movement replicating the surgeon’s hand movements made outside the field of the operation, elimination of tremor and superior ergonomics, suggesting possible application in both routine and more difficult cases.

Operator Learning Benefits

The main criticisms of robotic TME are the longer operating times and higher costs, compared to laparoscopic TME [13]. More widespread use of and familiarity with the robotic system has led to significant improvements in operation time, rates of conversion to open surgery and the number of harvested lymph nodes.

Bokhari et al. [14] suggested that the learning curve of robotic colorectal surgery was passed at 15 to 25. Kim et al. showed that the learning curve plateaued after 65 cases for Laparoscopic TME as opposed to 32 cases for Robotic TME [15].

Most studies to date about RLAR were done using the da Vinci Si system or older models. With the newer systems X or Xi, and once the surgeons have achieved at least 60 procedures we believe that the outcomes and operating time is less, that has been recently published by the ROLAR trial [11]. Similarly; to achieve good clinical and oncological outcomes with TaTME, surgeons are required to have performed at least 60 cases. Hence we decided to choose 60 procedures as an arbitrary number to select our surgeons experience involved in this trial.

Potential benefits of TaTME rectal resections

TaTME offers better access to the lower rectum in a difficult pelvis and also facilitate a clear distal margin by insertion of a distal to the tumour purse string under direct vision. This enables an end-to-end anastomosis without the need of multiple stapler firings. This approach also allows two-team synergy with an abdominal and perineal surgeon operating simultaneously.

The technique however still requires significant surgical skills and the ability to operate in a confined space.

The objective of this study is to compare TaTME and RLAR in expert hands. Outcome measures are mainly focused on differences in oncological long-term effects, see Table 1 for details.

Table 1

Trial specific primary and secondary outcome measures.


Primary Objective
3 year disease free survival after RLAR and TaTME
3 year disease free survival 6 monthly post op for the first 2 years and 12-monthly follow-up for next 3 years

Secondary/exploratory Objectives
Surgical morbidity/mortality up to 90 days
90 days

Pathological quality assessment Pathological assessment of mesorectum:
  1. Distal resected margin ≥1 cm
  2. Lymph node yield
  3. Mesorectal plane of surgery
  4. R0 resection (all margins clear)

Assessment of intraoperative adverse events To report “near misses” and associated impact upon clinical outcomes

Overall survival at 3 years

Health economics assessments Healthcare resource utilization (costs) including hospital length of stay, ICU hours, and productivity losses collected through a Labour Force survey). Return to work/activity will also be included

Evaluation of the operative length of time Total OR utilisation time and operative time skin to skin, minutes

Recruitment per month per centre for the RLAR and TaTME arms Patients dropout rate during follow-up will also be monitored



This is an observational prospective, multicentre trial. Patients will be assigned either RLAR or TaTME depends on the chosen centres. The centres do either TaTME or RLAR for rectal cancer management according to their training and experience. The study will include 330 patients from a number of international sites. This study has no impact on staging investigations, timing of surgery or any other aspect of the patients’ pre, peri or post-operative care. All decisions remain with the local clinician multi-disciplinary team including when to discharge from hospital. However, the biostatisticians performing the analysis will be blinded to the intervention. For study flow see Figure 1.

ROTA Study flow
Figure 1 

ROTA Study flow.

Study population

Participants with rectal cancer who are scheduled for initial treatment by TME by the MDT. The inclusion and exclusion criteria are shown in Table 2.

Table 2

Trial specific inclusion and exclusion criteria.


  • Participant is willing and able to give informed consent for participation in the trial.
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.

  • Male or Female, aged 18 years or older.
  • Participant with life expectancy of less than 6 months.

  • TME surgery for rectal cancer after MDT discussion.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.

  • Participant has no contra-indication to pelvic radiotherapy at the time of enrolment.
  • Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

  • In the Investigator’s opinion, is able and willing to comply with all trial requirements.

  • Tumour distance from anal verge – 12 cm or less

  • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.

The Number of Participants

The primary study end point, DFS is defined as the time following successful surgery to the first date of local, regional/distant relapse or death due to colorectal cancer (patients with secondary malignancy will be censored). Overall survival is defined as the time following successful surgery to death.

In the TaTME, it is assumed that the DFS is 92% and in the RLAR arm 95% at 3 years. A non-inferiority margin of 90% is selected. Based on this estimation, sample size calculation has been done with a one-sided level of significance of 20% and a power of 80%. A total number of 330 patients is needed, 165 patients in the RLAR arm and 165 patients in the TaTME are required with a 10% loss to follow-up assumed.

DFS will be analysed on an intent-to-treat (per protocol) basis using a log-rank test after propensity matching analysis has been conducted; a secondary analysis of DFS will also performed be using a Cox proportional hazards regression model with the unmatched cohort (without adjustment of baseline characteristics, i.e. propensity score match) that allowed for the effect of treatment and include lists of covariate with a statistical interaction of alpha level of 20%.

Data Management

Case report forms (CRFs) will be entered in a secured online page. Only authorized staff at sites will have access via an individual secure login username and password to enter the data. All paper CRFs must be completed, signed/dated and returned to the investigator. Data reported on each CRF should be consistent with the source data or discrepancies should be explained. If information is not known, this must be clearly indicated on the CRF. All missing or ambiguous data will be queried. All sections are to be completed.

All trial records will be archived and securely retained for at least 25 years.

Ethics and dissemination

The trial will be performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland and stated in the respective participating countries laws governing human research, and Good clinical Practice. The medical ethical committees of all participating countries will have to approve the study protocol prior to enrolling patients. The protocol has been approved by the Danish ethical committee of the Region of Southern Denmark with reference number S-20210038.


To date studies on TaTME and robotic TME have focused mainly on short term outcomes and oncological endpoints such as specimen quality, circumferential resection margin involvement and the free distal margin [13, 16, 17].

In a recent study comparing TaTME and Robotic TME, there were no differences in the incidence of poor quality. However the authors noted that distal resection margin (DRM) involvement was higher in the TaTME group [16]. They attributed this to the learning curve effect of TaTME. As discussed earlier, previous reports have noted that the learning curve for robotic TME was less than laparoscopic surgery, which in effect TaTME is still a laparoscopic “bottom up” approach.

Nonetheless, the long-term oncological parameters for both procedures, including overall survival, disease-free survival and local recurrence, are yet to be clarified. Secondly, there have been significant concerns in regards to an increased recurrence rate after TaTME [18]. The Norwegian group have noted an unexpected increase in local recurrence after TaTME of 9.5% after a median of 11 months after surgery [18]. The reasons for their observations is unclear, despite that fact that their surgeons performing TaTME were experienced and were proctored and trained in England and Spain for the procedure.

In 1980 Knight and Griffen [19] publised their stapling technique for low rectal cancer anastomosis using linear and circular stapler. This has led to the introduction of the double stapling technique [20]. The advantage is that the distal segment of the bowel is not opened and this avoids spillage from the rectal stump.

The possibility of increased local recurrences in TaTME may be related to the rectal transection and air flow during dissection from the perineum. The rectal purse-string suture is never completely air tight and this will invariably lead to shredding of microscopic cancer cells in the pelvis and hence this may lead to an increase rate of local recurrence. During a robotic TME and the use of the articulating robotic stapler, the rectal transection is precise and there are no leakage of microscopic cancer cells in the pelvis.

With these current issues in mind, we aim to compare the 3 year disease free survival and local recurrence rate of the two procedures performed by experienced surgeons who are beyond their learning curve. Only surgeons who have performed more than 60 procedures in either TaTME or robotic TME will be selected.

ROTA study will be the first multicentre prospective trial comparing RLAR and TaTME in regards to disease free survival (DFS) and other clinical trials.


There is an urgent need to assess and compare the long-term oncological outcomes of newer surgical techniques for TME (TaTME & RLAR). This will allow recommendations to be made for more tailor made treatment of rectal cancer, based on detailed outcomes from expert centers.


TME: Total Mesorectal Excision
TaTME: Transanal assisted Total Mesorectal Excision
RLAR: Robotic assisted Low Anterior Resection
RC: Rectal Cancer
DFS: Disease Free Survival
MDT: Multi Disciplinary Team
ICU: Intensive Care Unit
OR: Operating Room
TAMIS: Trans anal Minimally Invasive Surgery
CRM: Circumferential Resection Margin
BMI: Body Mass Index
RCT: Randomized Controlled Trial
DRM: Distal Resection Margin
CRF: Case Report Form

Ethics and Consent

The trial is approved by the ethical committee of the region of southern Denmark with case identification number S-20210038. The trial is registered I with id. Number NCT04200027.

Informed consent from the study participants will be obtained written and verbal as approved by the ethics committee.


We would like to acknowledge the lead of the department of surgery at Odense university Hospital, Denmark for their continuous support to the trial. Further, we would like to thank all our international partners for their willingness on collaboration in this trial.

Funding Information

The trial is externally funded by the Research foundation of the Region of Southern Denmark, Denmark. Funding is to secure the running costs of the study, including salary for the corresponding author, database establishment and publication fees.

Competing Interests

The authors have no competing interests to declare.

Author Contributions

All named authors agree to the submission of the paper to the journal. All authors who qualify for authorship have been listed on the paper; all the listed authors have participated in the concept and design of the trial. All the listed authors have contributed in the manuscript drafting and revising.

All authors has read and approved the manuscript.


  1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery–the clue to pelvic recurrence? Br J Surg. England; 1982 Oct; 69(10): 613–6. DOI: 

  2. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet (London, England). England; 1986 Jun; 1(8496): 1479–82. DOI: 

  3. van der Pas MH, Haglind E, Cuesta MA, Furst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. England; 2013 Mar; 14(3): 210–8. DOI: 

  4. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MHGM, de Lange-de Klerk ESM, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. United States; 2015 Apr; 372(14): 1324–32. DOI: 

  5. Jeong S-Y, Park JW, Nam BH, Kim S, Kang S-B, Lim S-B, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. England; 2014 Jun; 15(7): 767–74. DOI: 

  6. Kang S-B, Park JW, Jeong S-Y, Nam BH, Choi HS, Kim D-W, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol. England; 2010 Jul; 11(7): 637–45. DOI: 

  7. Hompes R, Guy R, Jones O, Lindsey I, Mortensen N, Cunningham C. Transanal total mesorectal excision with a side-to-end stapled anastomosis – a video vignette. Vol. 16, Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland. England; 2014; 567. DOI: 

  8. Sun Y, Xu H, Li Z, Han J, Song W, Wang J, et al. Robotic versus laparoscopic low anterior resection for rectal cancer: a meta-analysis. World J Surg Oncol. England; 2016 Mar; 14: 61. DOI: 

  9. Lee SH, Lim S, Kim JH, Lee KY. Robotic versus conventional laparoscopic surgery for rectal cancer: systematic review and meta-analysis. Ann Surg Treat Res. Korea (South); 2015 Oct; 89(4): 190–201. DOI: 

  10. Trastulli S, Farinella E, Cirocchi R, Cavaliere D, Avenia N, Sciannameo F, et al. Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Colorectal Dis. England; 2012 Apr; 14(4): e134–56. DOI: 

  11. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA. United States; 2017 Oct; 318(16): 1569–80. DOI: 

  12. Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H, et al. Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a meta-analysis. Ann Surg Oncol. United States; 2012 Nov; 19(12): 3727–36. DOI: 

  13. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, et al. Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases. Ann Surg. United States; 2017 Jul; 266(1): 111–7. DOI: 

  14. Perez D, Melling N, Biebl M, Reeh M, Baukloh J-K, Miro J, et al. Robotic low anterior resection versus transanal total mesorectal excision in rectal cancer: A comparison of 115 cases. Eur J Surg Oncol. England; 2018 Feb; 44(2): 237–42. DOI: 

  15. Kwak JM, Kim SH. Current status of robotic colorectal surgery. J Robot Surg. England; 2011 Mar; 5(1): 65–72. DOI: 

  16. Lee L, de Lacy B, Gomez Ruiz M, Liberman AS, Albert MR, Monson JRT, et al. A Multicenter Matched Comparison of Transanal and Robotic Total Mesorectal Excision for Mid and Low-rectal Adenocarcinoma. Ann Surg. United States; 2018 Jun. DOI: 

  17. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, et al. Incidence and Risk Factors for Anastomotic Failure in 1594 Patients Treated by Transanal Total Mesorectal Excision: Results From the International TaTME Registry. Ann Surg. United States; 2019 Apr; 269(4): 700–11. DOI: 

  18. Larsen SG, Pfeffer F, Korner H. Norwegian moratorium on transanal total mesorectal excision. Br J Surg. England; 2019 Aug; 106(9): 1120–1. DOI: 

  19. Knight CD, Griffen FD. An improved technique for low anterior resection of the rectum using the EEA stapler. Surgery. United States; 1980 Nov; 88(5): 710–4. 

  20. Cohen Z, Myers E, Langer B, Taylor B, Railton RH, Jamieson C. Double stapling technique for low anterior resection. Dis Colon Rectum. United States; 1983 Apr; 26(4): 231–5. DOI: